# A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

> **NCT00162500** · PHASE2 · WITHDRAWN · sponsor: **Hadassah Medical Organization** · enrollment: 15 (estimated)

## Conditions studied

- Multiple Myeloma
- Tumors

## Interventions

- **BIOLOGICAL:** Peptide Vaccine (MUC-1)

## Key facts

- **NCT ID:** NCT00162500
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2010-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162500, "A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00162500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*